LABStandard BioTools Inc.

$370M

Q1 2019 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$30M+19.3% YoY

Gross Profit

$17M56.4% margin

Operating Income

-$14M-47.2% margin

Net Income

-$25M-84.6% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

-6.8%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$291M

Total Liabilities

$109M

Stockholders' Equity

$182M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$25M	+19.3%
Gross Profit	$17M	$13M	+26.5%
Operating Income	-$14M	-$13M	-12.5%
Net Income	-$25M	-$13M	-92.2%

Revenue Segments

Total Products

$25M45%

Instruments

$13M23%

Consumables

$12M22%

Service

$5M10%

Geographic Segments

Americas

$13M43%

Asia Pacific

$9M30%

Europe

$8M27%

LAB Q1 2019 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena